Skip to search formSkip to main contentSkip to account menu

LEE011

Known as: LEE-011 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ribociclib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
A third of patients with triple negative breast cancer (TNBC) have relapsed disease within 2–5 years from initial diagnosis… 
2017
2017
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair
2017
2017
Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
Review
2016
Review
2016
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Review
2016
Review
2016
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future…
Dysregulation of the cyclin D-cyclin-dependent kinase (CDK) 4/6-INK4-retinoblastoma (Rb) pathway is an important contributor to… 
Review
2015
Review
2015
Targeting cell cycle regulators in hematologic malignancies
Hematologic malignancies represent the fourth most frequently diagnosed cancer in economically developed countries. In… 
Highly Cited
2015
Highly Cited
2015
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Purpose: Although significant progress has been made in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), many… 
Highly Cited
2014
Highly Cited
2014
Molecular Pathways Molecular Pathways : CDK 4 Inhibitors for Cancer Therapy
Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common. CDK4 is the key… 
Highly Cited
2014
Highly Cited
2014
A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.
2528^ Background: LEE011, an orally bioavailable, highly specific CDK4/6 inhibitor, causes cell cycle arrest and tumor growth… 
2014
2014
Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
535 Background: Aromatase inhibitors (AIs) are the recommended first-line endocrine therapy for postmenopausal (PM) patients (pts… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)